Atopic dermatitis is thought to be caused by allergic inflammation in response to various antigens in predisposed individuals, and is accompanied by an itching sensation. The scratching behavior often observed in patients with atopic dermatitis exacerbates the dermal inflammation.
1)
Histamine, which is released from mast cells and basophils on antigenic stimulation, plays a central role in itching. 2) Eosinophils have been implicated in the pathogenesis of allergic disease. An increase in the number of peripheral eosinophils and the concentration of eosinophil cationic protein in serum is related to the severity of atopic disease, 3) and deposits of eosinophil-derived granules are observed in chronic atopic dermatitis. 4) Thus, eosinophil infiltration is an important factor in allergic inflammation.
Topical glucocorticoids are generally used for the treatment of atopic dermatitis, and antihistamines are also administered to suppress the itching sensation. However, the use of glucocorticoids bring about side effects such as local skin atrophy, 1) and classical antihistamines have sedative side effects due to their interaction with central H 1 receptors. 5) Therefore, we planned to develop a new type of agent, having an inhibitory effect on eosinophil infiltration and antihistaminic activity without the sedative side effects.
We have observed that some fused pyridazine derivatives had an inhibitory effect on the leukotriene (LT) B 4 -stimulated chemotaxis of guinea pig peritoneal eosinophils. 6, 7) Then, we selected the fused pyridazine ring as a scaffold. Additionally, the incorporation of cyclic amines such as a piperidine or piperazine containing a benzhydryl group, both of which are in common in some antihistamines, may bring about antihistaminic activity. We describe here the synthesis and pharmacological evaluation of fused pyridazines having a cyclic amino group.
Chemistry
The synthesis of the desired [1, 2, 4] triazolo [1,5-b] pyridazines (5; listed in Table 1 ) and imidazo[1,2-b]pyridazines (6; listed in Table 3 ) was carried out via the route outlined in Chart 1. When the Z group, which is a linker between the fused ring and a cyclic amine containing a benzhydryl group, is NH or NCH 3 , the compounds 5 and 6 were synthesized by a one-step condensation of azoles (1, 2) and amines (3), or by a three-step sequence, i.e. amination of the azoles (1, 2) with aminoalcohols (7), mesylation of the resulting alcohols (10a, b), and amination with cyclic amines (11) . The compounds having an oxygen atom as a linker (5, 6; ZϭO) were synthesized by condensation of the azoles (1, 2) and alcohols (4) using a base. However, in the case of the ester derivative (6b), the trans-esterification mainly occurred in the reaction of the ethyl ester (2d) and the corresponding alcohol (4; nϭ3) in the presence of a base. Therefore, the azole substituted with a bulky ester group (2h) was used instead of 2c or 2d for the preparation of 6b (shown in Experimental section). The compounds having a sulfur atom as a linker (5, 6; ZϭS) were synthesized by the following method. The azoles (1, 2) were treated with ethyl 3-mercaptopropionate in the presence of sodium methoxide to afford 6-azolylthiolates, which were alkylated with 1-bromo-3-halogenated propanes (8) , and the resulting halides (10c, d) were condensed with the cyclic amines (11) . Imidazo [1,2-b] pyridazine with a carbon side chain introduced directly at the 6-position (6; ZϭCH 2 ) was obtained by cross coupling of the azole (2) and an organo zinc reagent 8) in the presence of dichlorobis(triphenylphosphine)palladium(II), followed by alkylation of the cyclic amine (11) with the resulting halide (10e).
A [1, 2, 4] triazolo [1,5-b] pyridazine ring having a tert-butyl group at the 2-position (1d) was constructed by the method shown in Chart 2. Condensation of 3-amino-6-chloropyridazine (12) 9) and a Vilsmeier-type reagent was followed by the treatment of the resulting amidine with hydroxylamine, which provided an amidoxime (14) . Cyclization of 14 using phosphorus oxychloride afforded a [1, 2, 4] triazolo [1,5-b] pyridazine skeleton (1d). The compound having a methoxycarbonyl group (1e) was synthesized by oxidation of 1c, 10) fol-lowed by esterification (Chart 3). Other [1, 2, 4] triazolo [1,5-b] pyridazines were prepared according to reported procedures. [10] [11] [12] Imidazo [1,2-b] pyridazines (2a-h) were synthesized as shown in Chart 4. Compound 12 was condensed with methyl 4-chloroacetoacetate (15) , and alkylation of the resulting 2i gave dialkylated or cycloalkylated compounds (2a-c). However, this method was found not to be adequate to afford the desired compounds in a large-scale preparation because of a deep coloration and a low yield. Therefore, an alternative route was investigated. The dimethyl group of the isobutylic acid moiety in 2d was introduced before construction of the imidazo[1,2-b]pyridazine ring; the dimethylated compound (16) 13) was used for condensation with 12. The ethyl ester (2d) obtained was hydrolyzed in an alkaline solution, and esterification of the resulting carboxylic acid (2j) using N,N-dimethylformamide di-tert-butylacetal gave the tert-butyl ester (2h). In addition, compound 2j was treated with N,NЈ-carbonyldiimidazole (CDI) and the resulting imidazolide was reduced using tetrabutylammonium borohydride to an alcohol (2e). Treatment of this imidazolide with amines also afforded the corresponding amides (2f, g).
The amines 3a-d were synthesized by condensation of the cyclic amines (11) [14] [15] [16] and N-(3-bromopropyl)phthalimide (17), followed by hydrazinolysis of the phthalimide group (Chart 5). The N-methylated compound (3e) was obtained by methoxycarbonylation of 3a with methyl chloroformate, followed by lithium aluminum hydride reduction.
Alkylation of the cyclic amines (11) with (bromoalkyl)alcohols (chart not shown) gave the corresponding alcohols (4; shown in Chart 1).
Results and Discussion
Screening Assays The compounds synthesized were initially tested for antihistaminic activity (in vitro and in vivo) and an inhibitory effect on eosinophil chemotaxis (in vitro). In vitro antihistaminic activity was assessed using isolated guinea pig tracheal strips. In vivo antihistaminic activity was evaluated from the inhibitory effect on the histamine-induced increase in microvascular permeability in the guinea pig skin. The inhibitory effect on the chemotaxis of guinea pig peritoneal eosinophils in response to LTB 4 was assessed using a modified Boyden's chamber method. TAK-225, 2-ethyl-2-[[ (7-methyl [1, 2, 4] triazolo [1,5- The effects of [1, 2, 4] triazolo [1,5-b] pyridazine derivatives (5) on the screening assays are summarized in Table 1 . It was found that most of the compounds listed in Table 1 have potent in vitro and in vivo antihistaminic activity, however, the introduction of an isopropyl group at the 7-position of the [1, 2, 4] triazolo [1,5-b] pyridazine ring (5d) attenuated in vivo activity.
In regard to eosinophil chemotaxis, the inhibitory activity of 5a having a piperidinyl group was higher than that of 5b having a piperazinyl group. Comparison of the atoms (Z) at the 6-position revealed that compounds having a nitrogen or oxygen atom as a linker had an increased inhibitory effect on eosinophil chemotaxis (compare 5a, 5c and 5e). With respect to the length of the carbon chains (n), the propylene group (nϭ3) had the most potent activity (compare 5a, 5f and 5g; 5c, 5h and 5i). In the case of the 2-substituted derivatives (R 3 ) (5j-m), the compounds having a nitrogen atom as a linker showed stronger activity compared with the compounds having an oxygen atom. The compound with a methoxycarbonyl group at the 2-position (5n) was more active than the compounds having a methyl group (5j) and a tert-butyl group (5l).
The compounds showing sufficient antihistaminic activity and inhibitory effect on eosinophil chemotaxis were evaluated for brain penetrability using an ex vivo binding assay in guinea pigs. The results are listed in Table 2 . The compounds not having a substituent at the 2-position (5a, 5c) completely inhibited the ex vivo [ 3 H]pyrilamine binding to H 1 receptors in both the lung and the cerebral cortex; 5a and 5c occupied H 1 receptors not only in the lung but also in the cerebral cortex. This result suggested that 5a and 5c easily permeated the blood-brain barrier (BBB). In the same way, the compounds having a methyl group (5j) or a methoxycarbonyl group (5n) at the 2-position also showed good brain penetrability. However, the introduction of a tert-butyl group (5l) decreased inhibition of the specific binding of [ It was reported that terfenadine, which has a tert-butyl group similar to 5l, shows cardiotoxicity when administered in overdoses, in patients suffering from a liver disease, or with ketoconazole or macrolide antibiotics. This toxicity is related to an increase in terfenadine plasma levels as a result of an inhibition of metabolism. These problems were solved by introduction of an isobutylic acid group instead of a tertbutyl group. 17, 18) Although it was not proven that compound 5l has the same side effect, we tried to convert the tert-butyl group into an isobutylic acid group. Additionally, the [1, 2, 4] In the eosinophil chemotaxis inhibition assay, compound 6a exhibited the most potent activity, and conversion of a nitrogen atom at the 6-position (6a) into an oxygen (6b) or a sulfur atom (6d) decreased the activity. As for the cyclic amines, the piperazine derivative (6f) and a compound having a hydroxy group (6h) showed less activity than 6a.
Compounds 6a, 6c, 6d, 6e, 6f and 6n, the carboxylic acid derivative of 6b, 19) were evaluated for their brain penetrability. As shown in Table 4 , the compound having a nitrogen atom as a linker (6a) was found to least effectively penetrate the brain in comparison with the compounds having a meth- ylene group (6c), a sulfur atom (6d) and an oxygen atom (6n). Methylation of the amino group of 6a (6e) and conversion of the piperidinyl group of 6a into a piperazinyl group (6f) increased brain penetrability.
Comparison between 6a and Its Metabolite 6o
The results of the screening assays revealed that 6a has a potent inhibitory effect on eosinophil chemotaxis and antihistaminic activity, besides showing little ability to cross of the BBB. Furthermore, a pharmacokinetic study of compound 6a revealed that it was rapidly metabolized to the carboxylic acid derivative (6o) when orally administered to guinea pigs (data not shown). We compared 6a and 6o in terms of antihistaminic activity and the inhibitory effect on eosinophil infiltration.
The in vitro and in vivo antihistaminic activity of compound 6o is shown in Table 5 . The compound showed antihistaminic activity in vitro at a concentration of 10 Ϫ5 M and in vivo when administered orally at a dose of 3 mg/kg. Additionally, on oral administration, 6o showed preferential peripheral binding similar to 6a.
The effect of 6a and 6o on antigen-induced eosinophil infiltration of the skin was evaluated in sensitized guinea pigs. 20) The results are listed in Table 5 . Both 6a and 6o significantly prevented eosinophils from infiltrating the skin at doses of 1 and 10 mg/kg, when administered orally.
Comparison of 6o with Antihistamines and Dexamethasone The antihistaminic activity and inhibitory effect on eosinophil infiltration of 6o were evaluated and compared with the reference compounds. The results are listed in Table 6 .
Compound 6o showed in vitro antihistaminic activity with an IC 50 value of 27.1 nM. It was found to be as potent as azelastine, 25-fold less potent than ketotifen, and 13-fold more potent than terfenadine. The in vivo antihistaminic activity of 6o was expressed as the dose required for 50% inhibition (ID 50 ) of the increase in microvascular permeability, which was 0.88 mg/kg (per os (p.o.)). Azelastine and ketotifen were found to be 20 and 30-fold more potent than 6o respectively, however, terfenadine was 1.5 fold less active than 6o.
The results of brain penetrability were expressed in ID 50 values, the dose required for 50% inhibition of [ 3 H]pyrilamine binding in the lung (ID 50 (L)) and the cerebral cortex (ID 50 (C)) of guinea pigs. A selectivity index between ID 50 (L) and ID 50 (C) is also listed as C/L. Compound 6o selectively decreased the specific binding of [ 3 H]pyrilamine to the lung membrane with an ID 50 value of 0.40 mg/kg, while the ID 50 (C) value was more than 300 mg/kg. In the case of known antihistamines, the selectivity index of terfenadine recognized as a non-sedative antihistamine showed that it has only a little ability to penetrate into the brain, while azelastine and ketotifen readily permeated the BBB in our experimental model.
The inhibitory effects of terfenadine and dexamethasone on eosinophil infiltration in guinea pigs were examined. Dexamethasone at 10 mg/kg, p.o. potently inhibited the infiltration of the skin. In contrast, terfenadine did not. These results suggested that the inhibition by 6o of eosinophil infiltration was due to a mechanism unrelated to its antihistaminic effect. In conclusion, we synthesized fused pyridazine derivatives having cyclic amines containing a benzhydryl group and evaluated their antihistaminic activity and inhibitory effect on eosinophil infiltration. Among the compounds tested, 6o showed potent activity, and also had reduced brain penetrability as suggested from the results of the ex vivo binding assay. Therefore, compound 6o (TAK-427) is expected to suppress dermal inflammation and intolerable itching sensations and is a promising drug candidate for the treatment of atopic dermatitis and allergic rhinitis. It is now under clinical investigation.
Experimental
Melting points (mp) were measured on a Yanagimoto micro melting point apparatus and are uncorrected. IR spectra were recorded on a Shimadzu FTIR-8200PC spectrometer. 6-chloro-7-isopropyl- 15) 4-(hydroxydiphenylmethyl)piperidine (11d), 16) 3-amino-6-chloropyridazine (12), 9) ethyl 4-bromo-2,2-dimethyl-3-oxobutyrate (16) 13) and azelastine 23) were prepared according to procedures described in the literature. Ketotifen, terfenadine and dexamethasone were purchased from Sigma.
N-(6-Chloropyridazin-3-yl)-N-hydroxy-2,2-dimethylpropanimidamide (14)
To a solution of N,N,2,2-tetramethylpropanamide (13) (36.0 g, 279 mmol) in toluene (85 ml) was added dropwise phosphorus oxychloride (18.5 g, 121 mmol) at 0°C, and the mixture was stirred at room temperature for 24 h. To this solution, 12 (12.0 g, 92.6 mmol) was added, followed by stirring at 60-70°C for 24 h. After cooling, the reaction mixture was diluted with ethyl acetate. The organic layer was washed with 2 N aqueous solution of sodium hydroxide and brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with hexane-ethyl acetate-triethylamine (25 : 25 : 1), and the desired fractions were concentrated. The resulting solid was collected by filtration and washed with diethyl ether to give 6.38 g of NЈ- (6-chloropyridazin-3-yl) -N,N,2,2-tetramethylpropanimidamide as colorless crystals. The filtrate concentrated was purified by column chromatography in a similar manner as previously described to give 6.07 g of the imidamide. A solution of hydroxylamine hydrochloride (4.31 g, 62.0 mmol) in methanol (40 ml) was added to a solution of the imidamide (12.4 g, 51.5 mmol) in methanol (60 ml), followed by stirring at room temperature for 2 h. After evaporation of half volume of the solvent, the crystalline precipitate was collected by filtration and washed with water and diethyl ether. The organic solvents of the filtrate were evaporated, and the resulting aqueous solution was extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The combined resulting crystals were collected by filtration and washed with diethyl ether to give 10.4 g of 14 (49% yield from 12), mp 128-130°C. 1 To a suspension of 14 (4.07 g, 17.8 mmol) in chloroform (170 ml) was added dropwise phosphorus oxychloride (13.6 g, 89.0 mmol), and the mixture was refluxed for 5 h. After cooling, the reaction mixture was poured into ice-cold aqueous solution of sodium hydroxide. The aqueous solution was separated and extracted with chloroform. The combined organic layer was washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with hexane-ethyl acetate (5 : 1), and the desired fractions were concentrated. The resulting solid was recrystallized from hexane-diethyl ether to give 1.12 g of 1d (30% yield) as light yellow crystals, mp 95-97°C. 1 Anal After ice-cold water (200 ml) was added to the reaction mixture at 0°C, the crystals precipitated were collected by filtration, washed with water and diethyl ether, and dried to give 9.74 g of 6-chloro [1, 2, 4] triazolo [1,5-b] pyridazine-2-carboxylic acid (83% yield). To a solution of the carboxylic acid (3.02 g, 15.2 mmol) in N,N-dimethylformamide (50 ml) was added N-ethyldiisopropylamine (3.15 ml, 18.3 mmol) and iodomethane (1.14 ml, 18.3 mmol) at 0°C. After stirring at room temperature for 19 h, ice-cold water and ethyl acetate were added. The crystalline precipitate was collected by filtration and washed with water and diethyl ether. Sodium chloride was added to the filtrate, followed by extraction of THF. The combined organic layer was dried and concentrated. The residue was purified by column chromatography on silica gel eluted with ethyl acetate, and the desired fractions were concentrated. The resulting crystals were washed with diethyl ether and dried to give 2.91 g of 1e (90% yield), mp 208-209°C. (15) (32.6 g, 217 mmol), and the mixture was refluxed for 21 h. After cooling, the solvent was evaporated. The residue was adjusted to pH 7 with an aqueous solution of sodium hydrogen carbonate and extracted with diethyl ether. The combined organic layer was washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with hexane-ethyl acetate (1 : 4), and the desired fractions were concentrated to give 11.8 g of 2i (48% yield) as purple crystals. in N,N-dimethylformamide (45 ml) was added sodium hydride (2.31 g, 57.8 mmol; 60% dispersion in oil) at 0°C, followed by stirring at room temperature for 40 min. 1,2-Dibromoethane (2.49 ml, 28.9 mmol) was added dropwise at 0°C, and the mixture was stirred at room temperature for 14 h. The reaction mixture was poured into ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with hexane-ethyl acetate (2 : 1), and the desired fractions were concentrated to give 3.67 g of methyl 1-(6-chloroimidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxylate (57% yield). To a solution of the methyl ester (4.14 g, 16.5 mmol) in ethanol (80 ml) was added slowly concentrated sulfuric acid (4.03 g, 41.1 mmol) at room temperature, and the mixture was refluxed for 36 h. After cooling, the solvent was evaporated. The residue was diluted with ice-cold water, neutralized with sodium hydrogen carbonate, and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated to give 3.39 g of 2b (77% yield) as crystals. in N,N-dimethylformamide (70 ml) was added sodium hydride (3.50 g, 89.1 mmol; 60% dispersion in oil) at 0°C, followed by stirring at room temperature for 30 min. Iodomethane (6.30 ml, 101 mmol) was added dropwise at 0°C, and the mixture was stirred at 0°C for 30 min and at room temperature for 5 h. The reaction mixture was poured into ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with hexane-ethyl acetate (1 : 1), and the desired fractions were concentrated. The resulting crystals were collected by filtration and washed with hexane to give 8. 
tert-Butyl 2-(6-Chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropionate (2h)
To a suspension of 2j (0.863 g, 3.60 mmol) in toluene (10 ml) was added N,N-dimethylformamide di-tert-butylacetal (2.59 ml, 10.8 mmol), and the mixture was stirred at 80°C for 1 h. After cooling, the reaction mixture was diluted with ethyl acetate, washed with an aqueous solution of sodium hydrogen carbonate, dried, and concentrated. The residue was crystallized from diethyl ether to give 0.520 g of 2h (48% yield). 
2-(6-Chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropanol (2e)
To a solution of 2j (0.719 g, 3.00 mmol) in tetrahydrofuran (15 ml) was added N,NЈ-carbonyldiimidazole (0.535 g, 3.30 mmol), and the mixture was stirred at room temperature for 1 h. Addition of tetra-n-butylammonium borohydride (1.15 g, 4.50 mmol) at 0°C to the mixture was followed by stirring at room temperature for 1 h. To the reaction mixture was added 5 N hydrochloric acid (2 ml), and the organic solvent was evaporated. The resulting aqueous residue was adjusted to pH 7 with an aqueous solution of sodium hydrogen carbonate and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with ethyl acetate, and the desired fractions were concentrated to give 0.488 g of 2e (72% yield) as crystals. 1 
2-(6-Chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropionamide (2f)
To a solution of 2j (1.20 g, 5.00 mmol) in N,N-dimethylformamide (8 ml) was added N,NЈ-carbonyldiimidazole (0.892 g, 5.50 mmol), and the mixture was stirred at room temperature for 30 min. To the mixture were added ammonium chloride (0.321 g, 6.00 mmol) and triethylamine (0.832 ml, 6.00 mmol) at 0°C, followed by stirring at room temperature for 3 h. After addition of ice-cold water to the reaction mixture, the crystalline precipitate was collected by filtration, washed with water, and dried to give 0.697 g of 2f. The filtrate was extracted with ethyl acetate, and the combined organic layer was washed with brine, dried, and concentrated. The resulting crystals were collected by filtration, washed with diethyl ether to give 0.229 g of 2f (total: 83% yield), mp 194-195°C. 
4-[Bis(4-fluorophenyl)methoxy]-1-piperidinepropanamine (3c)
To a solution of 4,4Ј-difluorobenzophenone (25.0 g, 114 mmol) in ethanoltetrahydrofuran (180-60 ml) was added sodium borohydride (2.16 g, 57.0 mmol) at 0°C, and the mixture was stirred at room temperature for 30 min. After evaporation of the solvents, the residue was diluted with icecold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated to give 29.2 g of bis(4-fluorophenyl)methanol as an oil. To a solution of the alcohol in toluene (800 ml) were added 4-hydroxypiperidine (11.6 g, 114 mmol) and p-toluenesulfonic acid monohydrate (23.7 g, 125 mmol), and the mixture was refluxed with Dean-Stark for 2 h. After cooling and evaporation of the solvent, the residue was diluted with ice-cold water and 1 N aqueous solution of sodium hydroxide (130 ml) and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated to give 34.5 g of 4-[bis(4-fluorophenyl)methoxy]piperidine (11c, crude, quantitative yield (from the benzophenone)). To a solution of the piperidine (23.0 g, equivalent to 76.0 mmol) and N- (3-bromopropyl) phthalimide (17) (16.3 g, 60.8 mmol) in N,Ndimethylformamide (100 ml) was added potassium carbonate (10.5 g, 76.0 mmol), and the mixture was stirred at room temperature for 20 h. The reaction mixture was diluted with ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with hexane-ethyl acetate (1 : 2), and the desired fractions were concentrated to give 20.5 
g of N-[3-[4-[bis(4-fluorophenyl)methoxy]piperidino]-
propyl]phthalimide (18c) (68% yield (from 17)) as an oil. To a solution of 18c (20.5 g, 41.7 mmol) in ethanol (150 ml) was added hydrazine monohydrate (2.02 ml, 41.6 mmol), and the mixture was refluxed for 3 h. After cooling and evaporating of the solvent, ethanol was added to the residue. The crystalline precipitate was collected, dissolved in 1 N aqueous solution of sodium hydroxide (40 ml), and extracted with ethyl acetate-tetrahydrofuran (2 : 1). The combined organic layer was washed with brine, dried, and concentrated to give 12.1 g of 3c (75% yield) as an oil. The following compounds, 3a and 3d, were prepared with a similar procedure described for the preparation of 3c.
4-(Diphenylmethoxy)-1-piperidinepropanamine (3a)
From 11a was prepared 3a (57% yield) as crystals, mp 41-43°C (from hexane). 14 mmol) and sodium hydrogen carbonate (0.109 g, 1.30 mmol) in tetrahydrofuran (3 ml) was added methyl chloroformate (0.10 ml, 1.30 mmol), and the mixture was stirred at room temperature for 30 min. The reaction mixture was diluted with ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The residue was dissolved in tetrahydrofuran (4 ml), followed by addition of lithium aluminum hydride (0.065 g, 1.71 mmol) at 0°C. The mixture was stirred for a few minutes under the same conditions and at 60°C for 1 h. After cooling, the reaction mixture was quenched with diethyl ether saturated with water, and then water was added to the mixture. The solid precipitated was removed by filtration, and the filtrate was concentrated to give 0.360 g of 3e (93% yield) as an oil. 
4-(Diphenylmethoxy)-1-piperidinepropanol (4a)
To a solution of 11a (1.61 g, 6.02 mmol) in N,N-dimethylformamide (30 ml) were added 3-bromopropanol (0.82 ml, 9.03 mmol) and potassium carbonate (1.66 g, 12.0 mmol), and the mixture was stirred at room temperature for 15 h. The reaction mixture was diluted with ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with ethyl acetate-methanol-triethylamine (90 : 10 : 1), and the desired fractions were concentrated to give 1.52 g of 4a (78% yield) as crystals, mp 62-64°C (from hexane-diethyl ether). 
4-(Diphenylmethoxy)-1-piperidineethanol (4b)
With a similar procedure described for the preparation of 4a, 4b was prepared from 11a and 2-bromoethanol (66% yield) as crystals. 1-piperidinebutanol (4c) To a solution of 11a  (1.05 g, 3.93 mmol) in N,N-dimethylformamide (10 ml) were added 4-bromobutyl acetate (0.57 ml, 3.93 mmol) and potassium carbonate (0.652 g, 4.72 mmol), and the mixture was stirred at 50°C for 3 h. After cooling, the reaction mixture was diluted with ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The residue was dissolved in ethanol (15 ml), and addition of 1 N aqueous solution of sodium hydroxide (8 ml) to the solution was followed by stirring at room temperature for 30 min. After evaporation of the solvent, the aqueous residue was neutralized with 1 N hydrochloric acid and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The resulting crystals were collected, washed with diethyl ether, and dried to give 1.21 g of 4c (91% yield), mp 176-178°C. After cooling, the solvent was evaporated, and ethyl acetate was added to the residue. The resulting solid was collected, washed with ethyl acetate, and suspended in tetrahydrofuran (40 ml). To the suspension was added 1,3-dibromopropane (8a) (3.06 ml, 30.0 mmol), the mixture was refluxed for 2 h. After cooling, the reaction mixture was diluted with ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. To the residue was added ethyl acetate, and the crystalline precipitate was collected and dried to give 1.97 g of 10c (72% yield), mp 133-135°C. 24 g, 34.2 mmol) , 8) and the mixture was stirred at 80°C under a nitrogen atmosphere for 3.5 h. After cooling, 2d (3.06 g, 11.4 mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.160 g, 0.228 mmol) were added to the reaction mixture, and the mixture was stirred at 80°C for 4 h. After cooling, the reaction mixture was diluted with water and ethyl acetate, and the insoluble material was filtered off through Celite ® . The organic layer was separated, washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with hexaneethyl acetate (1 : 1), and the desired fractions were concentrated to give 1.74 g of 10e (47% yield) as an oil. The following compounds, 5b and 5f, were prepared with a similar procedure described for the preparation of 5a. (0. 390 g, 1.20 mmol) in tetrahydrofuran (10 ml) was added sodium tert-butoxide (0.127 g, 1.32 mmol), and the mixture was refluxed for 30 min. After cooling, 1a (0.215 g, 1.39 mmol) was added, and the mixture was refluxed for 3 h. After cooling, the reaction mixture was diluted with ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with ethyl acetate-methanol-triethylamine (95 : 5 : 1), and the desired fractions were concentrated to give 0.383 g of the free base of 5c (71% yield). The free base (0.357 g, 0.800 mmol) was dissolved in ethanol, followed by addition of fumaric acid (0.093 g, 0.800 mmol). The resulting crystals were recrystallized from ethanol to give 0.218 g of 5c, mp 157-159°C. 1 The following compounds, 5d, 5h, 5i, 5k and 5m, were prepared with a similar procedure described for the preparation of 5c. and 11a (0.535 g, 2.00 mmol) in acetonitrile (15 ml) were added sodium iodide (0.373 g, 2.50 mmol) and potassium carbonate (0.277 g, 2.00 mmol), and the mixture was stirred at 50-60°C for 15 h. After cooling, the reaction mixture was diluted with ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluted with ethyl acetate-methanol-triethylamine (95 : 5 : 1), and the desired fractions were concentrated to give 0.630 g of the free base of 5e (68% yield). The free base of 5e was dissolved in ethanol, followed by addition of fumaric acid (0.159 g, 1.37 mmol). The resulting crystals were collected, washed with ethanol, and dried to give 0.435 g of 5e, mp 185-187°C. 74 (9H, m), 3.62 (3H, s), 5.64, 5.69 (each 0.5H, s), 7.20-7.42 (11H, m) 3 .60 mmol) in 1-butanol (30 ml) was added N-ethyldiisopropylamine (0.931 g, 7.20 mmol), and the mixture was refluxed for 14 h. After cooling and evaporation of the solvent, the reaction mixture was diluted with ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel eluted with ethyl acetate-methanoltriethylamine (45 : 5 : 1), and the desired fractions were concentrated. The resulting crystals were collected, washed with diethyl ether, and dried to give 0.149 g of 5g (36% yield), mp 102-104°C. 1 The following compounds, 5j, 5l and 5n, were prepared with a similar procedure described for the preparation of 5g. 
